CME/CE SYMPOSIUM

Addressing the Impacts of Iron Deficiency in HF:
Advances in Diagnosis and Management

Sunday, November 15, 2020 | 7:00 – 8:00 am, Dallas, TX

ACTIVITY TITLE

Addressing the Impacts of Iron Deficiency in HF: Advances in Diagnosis and Management

FORMAT

CME/CE Virtual Symposium

ACTIVITY DATE & LOCATION

Sunday, November 15, 2020 | 7:00 – 8:00 am (time subject to change)
Live Online

EDUCATIONAL GRANT SUPPORT

This educational activity is supported by an educational grant from American Regent.
This event is not part of the official Scientific Sessions 2020 as planned by the AHA Committee on Scientific Sessions Program.

TARGET AUDIENCE

This activity is designed for US-based healthcare professionals, including cardiologists, endocrinologists, primary care clinicians (PCPs), pharmacists, and other allied health professionals.

PROGRAM OVERVIEW

Iron deficiency (ID) affects up to one-third of the world's population and is particularly common in elderly individuals and those with heart failure (HF). Many of those affected are unaware of ID and cannot recognize its symptoms. For patients with HF, ID is an independent predictor of outcomes and a major contributor to exercise intolerance. At least half of all patients with HF have comorbid ID; yet, the condition is under-recognized and untreated in most patients.

In this symposium, experts will discuss data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity. Recent updates to established HF treatment guidelines that emphasize ID recognition and treatment will also be addressed. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

  • Review the prevalence and clinical burden of iron deficiency in HF patients
  • List current and emerging diagnostic approaches aimed to optimize the early diagnosis of ID in patients with HF
  • Interpret data about the efficacy and safety of intravenous iron repletion for the treatment of iron deficiency in HF patients
  • Identify individualized treatment regimens to manage ID in HF patients, including the administration of intravenous iron, based on the current evidence and guideline recommendations

FACULTY

Biykem Bozkurt, MD, PhD, FACC, FAHA

Biykem Bozkurt, MD, PhD, FACC, FAHA
The Mary and Gordon Cain and W.A. “Tex” and Deborah Moncrief, Jr., Chair
Professor of Medicine
Medical Care Line Executive, DeBakey VA Medical Center
Director, Winters Center for Heart Failure Research
Associate Director, Cardiovascular Research Institute
Baylor College of Medicine
Houston, TX

Gurusher S. Panjrath, MD, FACC, FAHA

Gurusher S. Panjrath, MD, FACC, FAHA
Director, Heart Failure and Mechanical Circulatory Support Program
Associate Professor of Medicine
George Washington University School of Medicine
Washington DC

PROGRAM AGENDA

I. Welcome and Introductions 7:00 - 7:05 am
II. Iron Deficiency in HF 7:05 - 7:20 am
III. Iron Repletion in HF: Evidence from Recent and Ongoing Clinical Trials 7:20 - 7:40 am
IV. Expert Roundtable: Clinical Case Presentation and Q&A 7:40 - 7:55 am
V. Conclusions 7:55 - 8:00 am

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Number (UAN): TBD

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Faculty disclosures will be provided.

Planners and Managers

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

REQUEST FOR CREDIT

Credit information to come.

FEE INFORMATION

There is no registration fee for this educational activity.